EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

DNA methylation-driven gene-based drug response prediction model for liver cancer: The critical role of GLS

Shuang Zheng, Xi Yu, Xiaozhou Wang, Yi Ma, Yujia Han, Jing Zhang, Wei Wu, Chunyu Sun, Lijie He iD

PLOS One · 2025

DOI: 10.1371/journal.pone.0338091 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Shuang Zheng und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The People's Hospital of Liaoning Province, People's Hospital of China Medical University, Shenyang, Liaoning, China. Hauptthemen laut MEDLINE: DNA Methylation, Liver Neoplasms, Carcinoma, Hepatocellular, Glutaminase. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Key Research and Development Projects of Liaoning Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Aberrant DNA methylation plays a pivotal role in cancer progression by enhancing oncogene activation or silencing tumor suppressor genes, contributing to malignant phenotypes. Methylation driver genes (MDGs) are characterized by an inverse correlation between DNA methylation levels and mRNA expression, making them critical targets for cancer research.

Methods

We analyzed the liver hepatocellular carcinoma (LIHC) dataset from The Cancer Genome Atlas (TCGA) using the R package MethylMix to identify MDGs. Prognostic models were developed through univariate Cox regression, least absolute shrinkage and selection operator (LASSO) regression, and multivariate Cox regression to identify core genes. We further evaluated the associations of these genes with the tumor immune microenvironment, immune checkpoint inhibitors (ICIs), and chemotherapeutic sensitivity. Finally, liver cancer tissue organoid culture experiments combined with DNA methylation sequencing were conducted to validate predictions of drug sensitivity.

Results

A total of 21 MDGs were identified, among which GNA14, glutaminase (GLS), and GNG4 were selected to construct a prognostic risk score model. The model demonstrated robust predictive performance, with Receiver Operating Characteristic (ROC) values of 0.723, 0.764, and 0.716 for 1-, 3-, and 5-year survival, respectively. Among these, GLS emerged as a key gene, showing low methylation levels and high mRNA expression, which were associated with poor prognosis, significant alterations in the tumor immune microenvironment, and differential sensitivity to ICIs and chemotherapeutic agents.

Conclusion

The three-gene MDG-based prognostic model effectively predicts survival outcomes in LIHC patients. Moreover, the methylation status of GLS serves as a biomarker for assessing immune microenvironment characteristics, responsiveness to immunotherapy, and chemotherapy sensitivity, highlighting its potential as a therapeutic target in liver cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DNA MethylationLiver NeoplasmsCarcinoma, HepatocellularGlutaminaseHumansTumor MicroenvironmentPrognosisMaleFemaleGene Expression Regulation, NeoplasticBiomarkers, TumorMiddle AgedImmune Checkpoint Inhibitors

Substanzen

GlutaminaseBiomarkers, TumorImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Oncology, The People's Hospital of Liaoning Province, People's Hospital of China Medical University, Shenyang, Liaoning, China.
  • School of Pharmacy, China Medical University, Shenyang, Liaoning, China.
  • Department of Hepatobiliary Surgery, The Sixth People's Hospital of Shenyang, Shenyang, Liaoning, China.

ORCID-Profile: Lijie He

Förderung

  • The Key Research and Development Projects of Liaoning Province

Zitieren

APA

Zheng, S., Yu, X., Wang, X., Ma, Y., Han, Y., Zhang, J., Wu, W., Sun, C., & He, L. (2025). DNA methylation-driven gene-based drug response prediction model for liver cancer: The critical role of GLS. PLOS One. https://doi.org/10.1371/journal.pone.0338091

Vancouver

Zheng S, Yu X, Wang X, Ma Y, Han Y, Zhang J, et al. DNA methylation-driven gene-based drug response prediction model for liver cancer: The critical role of GLS. PLOS One. 2025. doi:10.1371/journal.pone.0338091

BibTeX
@article{Zheng2025,
  author = {Zheng, Shuang and Yu, Xi and Wang, Xiaozhou and Ma, Yi and Han, Yujia and Zhang, Jing and Wu, Wei and Sun, Chunyu and He, Lijie},
  title = {DNA methylation-driven gene-based drug response prediction model for liver cancer: The critical role of GLS},
  journal = {PLOS One},
  year = {2025},
  doi = {10.1371/journal.pone.0338091}
}
Kostenlos starten →